77255-26-6

Basic information

• Product Name: 2-(4-Bromophenyl)cyclopropanecarboxylic acid
• Synonyms: 2-(4-Bromophenyl)-1-cyclopropanecarboxylic acid;2-(4-Bromophenyl)cyclopropane-1-carboxylic acid
• CAS NO: 77255-26-6
• Molecular Formula: C₁₀H₉BrO₂
• Molecular Weight: 241.09
• Mol File: 77255-26-6.mol
• Article Data: 19

Chemical Properties

• Melting Point: 122 °C
• Boiling Point: 364.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.652±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.53±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Bromophenyl)cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Bromophenyl)cyclopropanecarboxylic acid(77255-26-6)
• EPA Substance Registry System: 2-(4-Bromophenyl)cyclopropanecarboxylic acid(77255-26-6)

Safety Data

• Hazardous Substances Data: 77255-26-6(Hazardous Substances Data)

Usage

General Description

2-(4-Bromophenyl)cyclopropanecarboxylic acid is a chemical compound with the molecular formula C10H9BrO2. It is a cyclopropane derivative with a carboxylic acid functional group and a bromine substituent on the phenyl ring. 2-(4-Bromophenyl)cyclopropanecarboxylic acid is used in organic synthesis and drug development, and it may have potential pharmacological applications due to its unique structure and properties. Its synthesis and characterization are of interest to researchers in the fields of chemistry and pharmaceutical sciences.

Upstream product

• 2137065-16-6 (cis)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 1366440-18-7 tert-butyl 2-(4-bromophenyl)cyclopropanecarboxylate 
• 1122-91-4 4-bromo-benzaldehyde 
• 350490-15-2 tert-butyl (E)-3-(4-bromophenyl)prop-2-enoate 
• 939-90-2 trans-2-phenylcyclopropane-1-carboxylic acid 
• 939-89-9 (1S*,2R*)-2-phenylcyclopropane-1-carboxylic acid 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 1200-07-3 trans-4-bromocinnamic acid 
• 24393-53-1 ethyl (E)-3-(4-bromophenyl)-2-propenoate 
• 100115-96-6 4-Chlor-4-(4-brom-phenyl)-buttersaeureethylester 
• 1885-28-5 γ-(4-bromophenyl)-γ-butyrolactone 
• 134198-10-0 racemic 2-(4-bromo-phenyl)-trans-cyclopropanecarboxylic acid N-methoxy-N-methyl-amide 
• 53582-00-6 ethyl trans-2-(p-bromophenyl)-1-cyclopropanecarboxylate 
• 589-87-7 1,4-bromoiodobenzene 

Downstream Products

• 1123620-89-2 (1S,2S)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 31501-85-6 (R,R)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 1418287-95-2 (±)-trans-O-tert-butyl-N-(2-(4-bromophenyl)cyclopropyl)carbamate 
• 1366440-28-9 C₁₅H₁₈BrNO 
• 1000305-04-3 1-{[(1S,2S)-2-(4-bromophenyl)cyclopropyl]methyl}-(2S)-2-methylpyrrolidine 
• 90561-75-4 (1S,2R)-(+)-2-(4-bromophenyl)cyclopropyl-1-amine 

Relevant articles and documents

NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE

PROBLEM TO BE SOLVED: To provide a compound that specifically activates an LPA4 receptor, and a pharmaceutical composition containing the same. SOLUTION: This invention relates to a novel lysophosphatidic acid derivative that has an agonistic action on an LPA4 receptor and is useful for the prevention and/or treatment of a disease with angiodysplasia caused by the LPA4 receptor, or a disease associated with angiopathy, or symptoms associated therewith. This invention also relates to a pharmaceutical composition containing the lysophosphatidic acid derivative. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Free Carboxylic Acids

A monoprotected aminoethyl amine chiral ligand based on an ethylenediamine backbone was developed to achieve Pd-catalyzed enantioselective C(sp3)-H arylation of cyclopropanecarboxylic and 2-aminoisobutyric acids without using exogenous directing groups. This new chiral catalyst affords new disconnection for preparing diverse chiral carboxylic acids from simple starting materials that are complementary to the various ring forming approaches.

Synthesis and in vitro evaluation of novel N-cycloalkylcarbamates as potential cholinesterase inhibitors

Abstract: This present paper describes the preparation and characterization of a series of O-substituted N-cycloalkylcarbamate derivatives. These compounds were tested as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). All studied carbamates exhibited moderate inhibitory activity of both cholinesterases with values of IC50 in the range of 36.1–78.6?μM for AChE and 9.8–215.4?μM for BChE, respectively. These values are comparable with those values of inhibition obtained with the established drug rivastigmine. The cytotoxicity of all carbamates was evaluated using standard in vitro test with Jurkat cells. Many of the studied carbamates can be considered as promising compounds for potential medicinal applications with regard to their inhibitory activity as well as negligible cytotoxicity.